Variants at 8q24.21 have been shown to be associated with glioma development. By means of tag SNP genotyping and imputation, pooled next-generation sequencing using longrange PCR and subsequent validation SNP genotyping, we identified seven low-frequency SNPs at 8q24.21 that were strongly associated with glioma risk (P = 1 × 10 −25 to 1 × 10 −14 ). The most strongly associated SNP, rs55705857, remained highly significant after individual adjustment for the other top six SNPs and two previously published SNPs. After stratifying by histological and tumor genetic subtype, the most significant associations of rs55705857 were with oligodendroglial tumors and gliomas with mutant IDH1 or IDH2 (odds ratio (OR) = 5.1, P = 1.1 × 10 −31 and OR = 4.8, P = 6.6 × 10 −22 , respectively). Strong associations were observed for astrocytomas with mutated IDH1 or IDH2 (grades 2-4) (OR = 5.16-6.66, P = 4.7 × 10 −12 to 2.2 × 10 −8 ) but not for astrocytomas with wild-type IDH1 and IDH2 (smallest P = 0.26). The conserved sequence block that includes rs55705857 is consistently modeled as a microRNA.
We and others have previously shown that SNPs at 8q24.21 near CCDC26 are risk loci for oligodendroglial tumors and gliomas with mutated IDH1 or IDH2 (refs. 1-4) . To identify higher risk and/or low-frequency loci within 8q24.21, we used a two-stage study design consisting of tag SNP array genotyping and imputation in parallel with long-range PCR and pooled next-generation sequencing (NGS) (stage 1) followed by validation custom genotyping (stage 2) (Online Methods). Stage 1 used both imputation and pooled NGS because we were concerned that reliance on a single method might cause us to miss potentially important SNPs. We used two independent groups of cases (total n = 1,657: Mayo Clinic n = 852, University of California, San Francisco (UCSF) n = 805) and controls (total n = 1,301: Mayo Clinic n = 789, UCSF n = 512). Details on the subjects used in each stage are summarized in Supplementary Table 1 . Seven of the 157 SNPs genotyped in stage 2 (rs72714236, rs72714295, rs72714302, rs72716319, rs72716328, rs147958197 and rs55705857) were associated with glioma risk at high significance (Online Methods and Supplementary Table 2 ). The minor allele frequencies (MAFs) for these seven SNPs in all glioma cases ranged from 0.11 to 0.14, whereas in controls the MAFs ranged from 0.04 to 0.06 (P = 5 × 10 −25 to 3 × 10 −14 ; Supplementary Table 3) . Notably, rs55705857 was detected by the pooled NGS method; the remaining six SNPs were detected by imputation alone or by both imputation and pooled NGS (Supplementary Table 2 ). This observation suggests that, until variation in the human genome is mapped in greater detail, a combination of sequencing and imputation will continue to be necessary to identify low-frequency risk loci.
Stratification of cases by histological subtype showed differences in the strength of the SNP associations (Supplementary Table 3 ). The stage 2 associations with oligodendroglioma risk for the 157 SNPs at 8q24.21 (including the 7 most highly associated SNPs) are shown in Figure 1 . The results were very consistent between study sites A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation ( Supplementary Tables 2 and 3) . The strongest association, as measured by the size of the OR, was that of the G allele of rs55705857 (SNP 7 in Fig. 1 ) with the subgroup of oligodendroglioma cases versus controls, with this SNP having an OR of 6.3 (95% confidence interval (CI) = 4.6-8.8; P = 2.2 × 10 −28 ). The seven SNPs were also significantly associated with all other glioma subtypes examined (oligodendrogliomas, mixed oligoastrocytomas, grade 2-3 astrocytomas and glioblastomas (grade 4 astrocytomas)) (Supplementary Table 3) , with the strongest associations with rs55705857 (Fig. 2) .
IDH1 or IDH2 mutation occurs in approximately 50-80% of grade 2-3 gliomas and secondary glioblastomas but in less than 10% of primary glioblastomas [5] [6] [7] [8] . IDH gene mutation has been associated with younger age of onset and better survival in glioblastoma patients and with other somatic genetic and epigenetic alterations 9 . Notably, although rs55705857 (and the other six SNPs) were associated with risk of both IDH-mutated and IDH-wild type oligodendroglial tumors ( Fig. 2 and Supplementary Table 4), these SNPs were only associated with astrocytic gliomas with mutated IDH (World Health Organization (WHO) grade 2 and 3 astrocytomas and glioblastomas) but not with astrocytic gliomas with wild-type IDH. Specifically, in stage 2, rs55705857 showed strong associations with glioblastomas with mutated IDH1 or IDH2 (OR = 6.7, 95% CI = 3.4-12.9; P = 2.2 × 10 −8 ) and with grade 2 or 3 astrocytomas with mutated IDH1 or IDH2 (OR = 5.2, 95% CI = 3.2-8.2; P = 4.7 × 10 −12 ). However, the ORs were close to 1.0 and not significant for individuals with astrocytic glioma with wild-type IDH1 and IDH2. Although the sample sizes were relatively small for some glioma subtypes, the results were consistent between the two independent study sites (Supplementary Table 4) . Furthermore, the MAF for rs55705857 in the astrocytic cases with mutant IDH1 or IDH2 was nearly identical to the MAF for oligodendroglioma cases (MAF of ~0.20).
Co-deletion of both 1p and 19q is observed in 50-70% of oligodendrogliomas and mixed oligoastrocytomas and is associated with superior therapeutic response and survival 10, 11 . Of the 264 Mayo Clinic oligodendrogliomas and mixed oligoastrocytomas, 172 had 1p and 19q deletion data. In these gliomas, we observed an OR for rs55705857 of 6.5 (95% CI = 4.2-10; P = 9.5 × 10 −18 ) for the development of oligodendrogliomas and mixed oligoastrocytomas with co-deletion of 1p and 19q and an OR of 4.0 (95% CI = 2.4-6.8; P = 2.2 × 10 −7 ) for oligodendrogliomas and mixed oligoastrocytomas without codeletion of 1p and 19q in stage 2. Taken together, these results show that rs55705857 is associated with risk of oligodendroglial tumors, regardless of the 1p and 19q deletion and IDH mutation status of the tumors, but it is only associated with risk of astrocytic gliomas that harbor IDH mutations. Approximately 40% of individuals with these glioma subtypes carry one or more of the G risk alleles for rs55705857 compared to only about 8% of the controls. 
e t t e r s
The seven low-frequency SNPs identified here and the two previously reported SNPs 1 are all highly correlated. When individually adjusting for the other six low-frequency SNPs and the two reported SNPs, only rs55705857 remained significant (Supplementary Table 5) , with ORs ranging from 4.8 to 7.0 for gliomas of the oligodendroglial lineage. Thus, the primary association signal is due to rs55705857. Subsequent imputation in the validation panel did not identify additional SNPs with statistically stronger associations than those found for the original seven SNPs we identified. Thus, the reported association does not extend beyond the boundaries of the genotyped region (data not shown).
Associations of similar magnitude and significance to those observed here for rs55705857 with glioma subtypes have rarely been reported in cancer genome-wide association and subsequent finemapping studies [12] [13] [14] [15] . Indeed, the National Human Genome Research Institute (NHGRI) catalog (see URLs) currently lists only two cancer association studies with ORs greater than 4.0: one of those was for a variant for melanoma identified within high-risk pedigrees 12 , and another was for a variant associated with lung cancer survival 13 .
The risk region maps to a gene-poor section of 8q24 (Supplementary Fig. 1) . Some of the associated SNPs reside within the introns of CCDC26, a predicted long noncoding RNA (lncRNA) gene. The risk SNP with the most significant association, rs55705857, resides in a conserved cluster (PhastCons track, UCSC Genome Browser) from 130,645,483 to 130,645,975 bp. Fifteen base pairs (including rs55705857) are 100% conserved from platypus to human (Supplementary Fig. 1 ). The functional relevance of the conserved region is not known, and functional annotation of the region is limited. However, structural modeling indicates that the conserved region might encode a novel lncRNA or a microRNA (data not shown). The conserved elements include the predicted unpaired loops of a microRNA, and rs55705857 lies within the seed sequence of the putative microRNA, an observation that could have functional relevance 16 . Alternatively, there may be long-and short-range interactions between this highly conserved region and other critical regions of the genome, or there might be other causative variants that our methods have not detected.
Our data show that variants within the 8q24.21 region are associated with specific morphological and molecular glioma subtypes. Similar subtype-specific associations have recently been observed in other cancers. Variants at 5p12, 8q24 (~1.5 Mb proximal to the variants reported here), 9p21, 10q21 and 11q13 are associated with estrogen receptor-positive but not with estrogen receptor-negative breast cancers 17 . Variants at 19p13 are associated with triple-negative breast cancer 17 . Variants at 5p15 are associated with different histological types of lung cancer 18 . Serous ovarian cancer is associated with variants at 8q24 (also ~1.5 Mb proximal to the variants reported here) 19 . Distinct variants are associated with other ovarian cancer subtypes 20 . The ORs for all these associations are less than 1.5. In aggregate, the implication of these data is that morphological and molecular subtyping is critical to cancer genetic epidemiology.
Variants within the 8q24 gene desert, including the CCDC26 region, are associated with risk of multiple cancers 19, [21] [22] [23] . The ORs for these associations do not approach the strength we observed for rs55705857 in glioma risk. As most of these other cancer-associated variants are ~1.5 Mb proximal to the region reported here 19, [21] [22] [23] , one possible hypothesis is that synthetic association and/or long-range linkage disequilibrium is the basis for some of these associations 24 .
Somatic IDH1 or IDH2 mutation in glioma is associated with a characteristic DNA methylation pattern 6, 25 , a specific histone modification pattern 26, 27 and a stem cell-like phenotype 25, 26 . Our results strongly suggest that the glioma risk locus in the 8q24 (CCDC26) region identified in the present study might interact with IDH gene mutations and/or the downstream effects of such mutations to facilitate the development and progression of gliomas. An alternative explanation might be that variants in this region promote formation of IDH1 or IDH2 mutations. That oligodendroglial tumors without IDH1 or IDH2 mutation are also strongly associated with this risk locus suggests that alterations within these tumors may arise or be maintained by mechanisms similar to (but distinct from) IDH gene mutation.
URLs. Catalog of Published Genome-Wide Association Studies, http://www.genome.gov/gwastudies/.
MeThOdS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.

ONLINe MeThOdS
Study design. The overall study design is summarized in Supplementary  Figure 2 . The study had two stages. Stage 1 consisted of imputation of a previous 8q24 tag SNP genotyping data set 2 (stage 1a) and pooled NGS using long-range PCR (stage 1b Mayo Clinic case-control study. Details of subject recruitment for the Mayo Clinic case-control series have been reported previously 2, 28 . A total of 860 cases and 795 controls from the Mayo Clinic were used in this study. Stage 1a used 582 glioma cases and 532 controls, stage 1b used 220 oligodendroglioma cases and 274 controls, and stage 2 used 852 glioma cases and 789 controls (693 of these cases and 578 of the controls were also used in stage 1).
UCSF case-control study. UCSF cases and controls were taken from the San Francisco Bay Area Adult Glioma Study (AGS). Details of subject recruitment for AGS have been reported previously [28] [29] [30] . A total of 953 cases and 1,079 controls from the UCSF AGS were used in this study. Stage 1a used 191 oligodendroglioma cases and 192 controls, stage 1b used 177 oligodendroglioma cases and 547 controls, and stage 2 used 805 glioma cases and 512 controls (182 of these cases but none of the controls were also used in stage 1).
Pathology review and IDH1 and IDH2 mutation and 1p and 19q deletion analyses. Pathology review was performed by two pathologists as previously described 28 . IDH1 and IDH2 mutation analysis and testing for 1p and 19q deletions were performed using previously described methods 6, 31 .
Long-range PCR and pooled NGS (stage 1b).
Two peaks of association at 8q24.21 between 130.435-130.526 Mb and 130.624-130.699 Mb were previously observed 2 . We prepared four pools of DNA-two from oligodendroglial cases (n = 177 for UCSF and 220 for the Mayo Clinic) and two from controls (n = 547 for UCSF and 274 for the Mayo Clinic)-and subjected each to longrange PCR covering the two peaks, followed by NGS (to a target depth of 2,000×) by deCODE Genetics 22 . The final sequence coverage for each pool is summarized in Supplementary Figure 3 .
For quality control, MAFs for common variants with prior genotyping data 2 and MAFs estimated by NGS were compared (Supplementary Fig. 4) . Concordant MAFs (MAFs that differed by less than 0.10 in frequency) were found for 74 of 77 (96%) of these common SNPs.
Validation custom genotyping (stage 2).
Candidate selected SNPs (see Statistical Methods) from imputation of the tag SNP panel and the long-range PCR and pooled NGS studies were validated using custom genotyping. GoldenGate assays were designed by Illumina and were performed using the Illumina VeraCode platform. Genotyping was performed by the Mayo Clinic Genotyping Core and the UCSF Genomics Core. Samples were submitted in 96-well plates. Each plate contained several intra-and interplate replicates.
Statistical methods. Imputation and statistical analysis in stage 1a.
Quality control and statistical analysis methods for the 96 SNPs genotyped on the previous 8q24 tag SNP panel were previously reported for samples from the Mayo Clinic and UCSF 2 . The 96 SNPs in this previously published data set were nonredundant, had MAFs greater than 5% and covered a 322-kb region encompassing the two previously defined association peaks 1, 2 . In this study, imputation was performed separately for the Mayo Clinic and UCSF data using MACH 32 with 1000 Genomes Project data serving as the reference population. The region that was imputed spanned both peaks identified in the previous publications 1, 2 , the 'valley' between the peaks and the regions 250 kb centromeric and telomeric to the peaks. Imputation also included areas not covered by the final long-range PCR and pooled NGS results. Over 4,000 SNPs with a quality score of >0.25 (r 2 ) were separately imputed using both the UCSF and Mayo Clinic cases with gliomas of oligodendroglial lineage.
Statistical analysis of stage 1b. Two statistical methods were used to analyze the deCODE NGS data. First, deCODE provided association results based on a likelihood-ratio test comparing the MAF of a variant in the case and control pools 22 . Second, the deCODE data were locally reanalyzed. Allele frequencies were calculated on the basis of read counts, with calculations performed separately for reads generated from each case and control pool. For quality control, variants were removed that had fewer than 1,000 read counts (poorly covered regions generate inaccurate allele frequency estimates). Variants whose allele frequency estimates differed more than 10% between the two case pools and between the two control pools were also removed. On the basis of the derived allele frequencies, the number of chromosomes in the original pools carrying various alleles was estimated. Association tests were conducted using Fisher's exact test for the estimated number of chromosomes carrying the minor alleles in the corresponding case and control pools.
SNP selection for validation genotyping.
Results from both the observed and imputed previous 8q24 tag SNP panel 2 and the pooled NGS data were used to identify SNPs for validation genotyping. We chose SNPs that were significantly associated with glioma across four analyses: (i) imputation of Mayo Clinic data within the previous 8q24 tag SNP panel 2 ; (ii) imputation of UCSF data within the previous 8q24 tag SNP panel 2 ; (iii) deCODE analysis of NGS data; and (iv) UCSF and Mayo Clinic reanalysis of NGS data. Significance was defined as P < 0.05. Candidates for validation included those meeting any of the following five criteria: (i) SNPs significant in all four analyses; (ii) SNPs significant in three of the four analyses; (iii) SNPs significant in two of the four analyses, including one analysis with imputation and one with NGS data; (iv) NGS SNPs with case or control frequencies of <10% that were significant in both NGS analyses only (this criterion aimed to identify rare variants that were not genotyped by the previous 8q24 tag SNP panel 2 ); and (v) SNPs significant in both of the imputation analyses only (this criterion aimed to identify SNPs that failed NGS). There were a total of 129 SNPs in the 8q24.21 region that met one of these five criteria (Supplementary Fig. 5 ). Of these SNPs, 104 were on the previous tag array 2 , were in high linkage disequilibrium with the previously reported SNPs or had high MAFs (>0.10). We selected the remaining 25 SNPs, 8 8q24 associated literature SNPs 1 and 38 8q24 tag SNPs 2 , as well as 155 additional SNPs that were highly significant in a single imputation or NGS analysis. A total of 226 SNPs were selected for further custom SNP array design and analysis. Of these, 182 SNPs passed the design phase (44 SNPs had low design scores or were adjacent to other SNPs).
Quality control and statistical analysis of stage 2. Samples with call rates of <0.9 and <0.975 in the Mayo Clinic (n = 12) and UCSF (n = 3) series, respectively, were excluded from analysis. Subsequently, SNPs with call rates of <0.9 and <0.975 in the Mayo Clinic (n = 31) and UCSF (n = 31) series, respectively, were excluded from analysis (16 in common between the series). Because a custom chip containing infrequent variants was used, no MAF exclusions were made. SNPs with Hardy-Weinberg equilibrium P values of <0.001 in control subjects were excluded (n = 4 for the Mayo Clinic and 4 for the UCSF series; none in common). Identity by descent was evaluated 33 , and two individuals from the Mayo Clinic and UCSF series seemed to be related; the two individuals from the UCSF series were removed for all pooled analyses. Informative custom Illumina genotyping was successful at the Mayo Clinic and/or UCSF for 157 SNPs (Supplementary Table 2 ).
An additive logistic regression model for zero, one or two copies of the minor allele was used to investigate the association of glioma risk for each SNP. The Mayo Clinic and UCSF series were first analyzed separately, and, subsequently, a pooled analysis was performed. Analyses were performed for all cases versus controls, and cases were subsequently stratified by tumor histology, IDH gene mutation status and 1p and 19q deletion status. All analyses were adjusted for both age and gender; pooled analyses were also adjusted for study site.
For the seven low-frequency SNPs identified, dominant and genotypic models were also used to test association, and no notable differences from the additive model were found (data not shown). There were too few homozygotes for the npg
